Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 9/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 5/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | CALML3 | P27482 | 1/20 | 0.31 |
| ▸ | SDHA | P31040 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041712 | 1.00 | MAOA (0.39) | MAOAGRM2KDM4EMAPK1L3MBTL1 | |
| SCHEMBL3034801 | 0.89 | MAOA (0.52) | MAOAGRM2MAOB | |
| SCHEMBL3041204 | 0.89 | MAOA (0.52) | MAOAGRM2MAOB | |
| SCHEMBL3043259 | 0.87 | MAOA (0.40) | MAOAGRM2KDM4EMAPK1L3MBTL1 | |
| SCHEMBL3039264 | 0.84 | GRM2 (0.40) | GRM2KDM4EMAPK1L3MBTL1 | |
| SCHEMBL3035177 | 0.84 | GRM2 (0.40) | GRM2KDM4EMAPK1L3MBTL1 | |
| SCHEMBL5763150 | 0.81 | MAOA (0.44) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5762911 | 0.81 | MAOA (0.44) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5762913 | 0.81 | MAOA (0.44) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL3034814 | 0.81 | MAOA (0.55) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885GRM2 2255/4885KDM4E 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.